Sex/gender effects of glial reactivity on preclinical Alzheimer's disease pathology
- PMID: 39384963
- PMCID: PMC11919761
- DOI: 10.1038/s41380-024-02753-9
Sex/gender effects of glial reactivity on preclinical Alzheimer's disease pathology
Abstract
Glial reactivity may contribute to sex/gender differences in Alzheimer's disease (AD) pathophysiology. Here, we investigated the differential effect of cerebrospinal fluid (CSF) glial markers on AD pathology and neurodegeneration by sex/gender among cognitively unimpaired older adults at increased risk of developing AD. We included 397 participants from the ALFA+ cohort with CSF Aβ42/40, p-tau181, sTREM2, YKL40, and GFAP, magnetic resonance imaging-based hippocampal volume (n = 299), and amyloid burden (centiloids) measured with [18F] flutemetamol positron emission tomography (n = 341). We ran multiple linear regression models to assess the association between glial markers, AD pathology and hippocampal volumes and their interaction with sex/gender, using False Discovery Rate to correct for multiple comparisons. Glial markers significantly contributed to explain amyloid burden, tau pathology, and hippocampal volumes, beyond age and/or primary AD pathology in a sex/gender-specific manner. Compared to men, women showed increased amyloid burden (centiloids) and CSF p-tau181 with increasing levels of sTREM2 and YKL40, and YKL40 and GFAP, respectively. Compared to women, men with greater tau burden showed lower hippocampal volumes as CSF YKL40 levels increased. Overall, our findings suggest that glial reactivity may contribute to sex/gender differences in AD progression, mostly, downstream amyloid. Further research identifying sex/gender-specific temporal dynamics in AD development is warranted to inform clinical trials.
© 2024. The Author(s).
Conflict of interest statement
Competing interests: CV-C, MA, EP, PA-D, GO, KB, JD-G, CF, KFC and EMAU report no conflict of interest. HZ has served at scientific advisory boards and/or as a consultant for Abbvie, Acumen, Alector, Alzinova, ALZPath, Annexon, Apellis, Artery Therapeutics, AZTherapies, Cognito Therapeutics, CogRx, Denali, Eisai, Merry Life, Nervgen, Novo Nordisk, Optoceutics, Passage Bio, Pinteon Therapeutics, Prothena, Red Abbey Labs, reMYND, Roche, Samumed, Siemens Healthineers, Triplet Therapeutics, and Wave, has given lectures in symposia sponsored by Alzecure, Biogen, Cellectricon, Fujirebio, Lilly, and Roche, and is a co-founder of Brain Biomarker Solutions in Gothenburg AB (BBS), which is a part of the GU Ventures Incubator Program (outside submitted work). OG-R has given lectures in symposia sponsored by Roche Diagnostics, and receives support for research (to the institution) from F- Hoffmann La Roche. GK is a full‑time employee of Roche Diagnostics GmbH. CQ-R is a full‑time employee of Roche Diagnostics International Ltd. MS-C has given lectures in symposia sponsored by Roche Diagnostics, S.L.U, Roche Farma, S.A, Eli Lilly and Amirall, he has served as a consultant and at advisory boards for Roche Diagnostics International Ltd and Grifols S.L. He was granted with a project funded by Roche Diagnostics International Ltd. All payments were made to the institution (BBRC). He received in-kind support for research (to the institution) from Roche Diagnostics International Ltd, Avid Radiopharmaceuticals, Inc., Eli Lilly and Janssen Research & Development.
Figures
Comment in
-
Immune responses influence sex differences in Alzheimer disease.Nat Rev Neurol. 2024 Dec;20(12):691. doi: 10.1038/s41582-024-01044-9. Nat Rev Neurol. 2024. PMID: 39538024 No abstract available.
References
-
- Vila-Castelar C, Tariot PN, Sink KM, Clayton D, Langbaum JB, Thomas RG, et al. Sex differences in cognitive resilience in preclinical autosomal-dominant Alzheimer’s disease carriers and non-carriers: Baseline findings from the API ADAD Colombia Trial. Alzheimers Dement. 2022;18:2272–82. - PMC - PubMed
MeSH terms
Substances
Grants and funding
- PI22/00456/Ministry of Economy and Competitiveness | Instituto de Salud Carlos III (Institute of Health Carlos III)
- K99 AG073452/AG/NIA NIH HHS/United States
- 100010434/"la Caixa" Foundation (Caixa Foundation)
- JPND2022-138/EU Joint Programme - Neurodegenerative Disease Research (Programi i Përbashkët i BE-së për Kërkimet mbi Sëmundjet Neuro-degjeneruese)
- PI19/00155/Ministry of Economy and Competitiveness | Instituto de Salud Carlos III (Institute of Health Carlos III)
- K99AG073452/U.S. Department of Health & Human Services | NIH | National Institute on Aging (U.S. National Institute on Aging)
- JPND2021-00694/EU Joint Programme - Neurodegenerative Disease Research (Programi i Përbashkët i BE-së për Kërkimet mbi Sëmundjet Neuro-degjeneruese)
- AARG 2019-AARG-644641/Alzheimer's Association
- AARG 2019-AARG-644641-RAPID/Alzheimer's Association
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous
